Developing locally-enhanced topical products that are scientifically proven to have significantly better penetration and retention with a time-released effect
Our “Zol” Formulations
Mission
Developing locally-enhanced topical transdermal products to disrupt existing markets
Science
Topical formulations need to be able to penetrate the skin and permeate to the target areas in quantities sufficient to exert a therapeutic effect.
Data available indicate that topical diclofenac can penetrate and permeate to deeper tissues, with a lower plasma to tissue ratio than oral diclofenac.
Diclofenac can penetrate the skin and permeate to deeper tissues, where it reaches a concentration that appears to be sufficient to exert a therapeutic effect.
Martina Hagen & Mark Baker (2017) Skin penetration and tissue permeation after topical administration of diclofenac, Current Medical Research and Opinion, 33:9, 1623-1634, DOI: 10.1080/03007995.2017.1352497
PERMEATION
- At early hours, Nex-Zol gel exhibited superior permeation.
- After 24 hr, at least 7 fold of permeation enhancement was observed with the Nex-Zol formulation.
FLUX
Nex-Zol Formulation vs. Leading Competition
- The rate of penetration for The Zol formulation is significantly higher at all time points.
- Effect continues over time as competition falls off.
- Zol demonstrates a time-released effect with single and multiple applications
Our Investors
We are actively seeking investors and development partners.
Please contact Joel Carden, Investors Relations
- C: 833-639-9651
- jcarden@nexzol.com
- 1001 Avenida Pico, Suite C-501, San Clemente, CA 92673